CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		127,369,142
Beginning balance at Dec. 31, 2023	$ 941,537	$ 127	$ 1,190,139	$ (1,674)	$ (247,055)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for ESPP (in shares)		70,278
Issuance of common stock for ESPP	917		917
Issuance of restricted stock, net of forfeitures (in shares)		(17,398)
Issuance of restricted stock, net of forfeitures	(199)		(199)
Issuance of common stock for stock options (in shares)		12,764
Issuance of common stock for stock options	102		102
Stock issuance fees and expenses	(4)		(4)
Stock-based compensation expense	7,774		7,774
Net unrealized gain on marketable securities, net of tax	344			344
Net (loss) income	(27,061)				(27,061)
Ending balance (in shares) at Mar. 31, 2024		127,434,786
Ending balance at Mar. 31, 2024	923,410	$ 127	1,198,729	(1,330)	(274,116)
Beginning balance (in shares) at Dec. 31, 2023		127,369,142
Beginning balance at Dec. 31, 2023	941,537	$ 127	1,190,139	(1,674)	(247,055)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized gain on marketable securities, net of tax	652
Net (loss) income	(45,703)
Ending balance (in shares) at Jun. 30, 2024		127,851,113
Ending balance at Jun. 30, 2024	915,884	$ 128	1,209,536	(1,022)	(292,758)
Beginning balance (in shares) at Mar. 31, 2024		127,434,786
Beginning balance at Mar. 31, 2024	923,410	$ 127	1,198,729	(1,330)	(274,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for ESPP (in shares)		102,112
Issuance of common stock for ESPP	1,280		1,280
Issuance of restricted stock, net of forfeitures (in shares)		32,607
Issuance of restricted stock, net of forfeitures	(1,631)		(1,631)
Issuance of common stock for stock options (in shares)		281,608
Issuance of common stock for stock options	2,321	$ 1	2,320
Stock issuance fees and expenses	(3)		(3)
Stock-based compensation expense	8,841		8,841
Net unrealized gain on marketable securities, net of tax	308			308
Net (loss) income	(18,642)				(18,642)
Ending balance (in shares) at Jun. 30, 2024		127,851,113
Ending balance at Jun. 30, 2024	$ 915,884	$ 128	1,209,536	(1,022)	(292,758)
Beginning balance (in shares) at Dec. 31, 2024	128,145,333	128,145,333
Beginning balance at Dec. 31, 2024	$ 902,339	$ 128	1,228,198	(206)	(325,781)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for ESPP (in shares)		132,961
Issuance of common stock for ESPP	1,424		1,424
Issuance of restricted stock, net of forfeitures (in shares)		70,829
Issuance of restricted stock, net of forfeitures	(530)		(530)
Issuance of common stock for stock options (in shares)		7,204
Issuance of common stock for stock options	58		58
Stock issuance fees and expenses	(3)		(3)
Stock-based compensation expense	10,754		10,754
Net unrealized gain on marketable securities, net of tax	150			150
Net (loss) income	(25,923)				(25,923)
Ending balance (in shares) at Mar. 31, 2025		128,356,327
Ending balance at Mar. 31, 2025	$ 888,269	$ 128	1,239,901	(56)	(351,704)
Beginning balance (in shares) at Dec. 31, 2024	128,145,333	128,145,333
Beginning balance at Dec. 31, 2024	$ 902,339	$ 128	1,228,198	(206)	(325,781)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for stock options (in shares)	9,083
Net unrealized gain on marketable securities, net of tax	$ 235
Net (loss) income	$ (71,015)
Ending balance (in shares) at Jun. 30, 2025	128,681,713	128,681,713
Ending balance at Jun. 30, 2025	$ 854,040	$ 128	1,250,679	29	(396,796)
Beginning balance (in shares) at Mar. 31, 2025		128,356,327
Beginning balance at Mar. 31, 2025	888,269	$ 128	1,239,901	(56)	(351,704)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for ESPP (in shares)		135,778
Issuance of common stock for ESPP	847		847
Issuance of restricted stock, net of forfeitures (in shares)		187,729
Issuance of restricted stock, net of forfeitures	(2,297)		(2,297)
Issuance of common stock for stock options (in shares)		1,879
Issuance of common stock for stock options	16		16
Stock issuance fees and expenses	(3)		(3)
Stock-based compensation expense	12,215		12,215
Net unrealized gain on marketable securities, net of tax	85			85
Net (loss) income	$ (45,092)				(45,092)
Ending balance (in shares) at Jun. 30, 2025	128,681,713	128,681,713
Ending balance at Jun. 30, 2025	$ 854,040	$ 128	$ 1,250,679	$ 29	$ (396,796)

NEOGENOMICS INC 10-Q